Table 1.
General characteristics of the ASRI cohort
| Included n | Median (IQR) or n(%) | Range | |
|---|---|---|---|
| Demographics and disease characterisation | |||
| Gender (male %) | 912 | 75.1 | -- |
| Age, median (IQR) | 912 | 44 (36–55) | 18–85 |
| Age at AxSpA symptom onset, median (IQR) | 906 | 25 (19–33) | 7–78 |
| Age at diagnosis, median (IQR) | 906 | 34 (26–42) | 9–80 |
| Delay to diagnosis in years, median (IQR) | 906 | 6 (2–11) | 0–52 |
| Disease duration in years, median (IQR) | 912 | 16 (9–27) | 0–57 |
| ASAS criteria for AxSpA, n (%) | 912 | 912 (100) | -- |
| mNY criteria for AS, n (%) | 912 | 694 (76.1) | -- |
| HLA-B27 positive, n (%) | 863 | 733 (84.9) | -- |
| Clinical measures of disease activity and severity | |||
| BASDAI score, median (IQR) | 912 | 3.7 (1.9–5.8) | 0.0–10.0 |
| BASMI score, median (IQR) | 912 | 3.6 (2.4–5.6) | 0.4–9.0 |
| BASFI score, median (IQR) | 912 | 3.2 (1.3–5.6) | 0.0–10.0 |
| AsQoL score, median (IQR) | 912 | 5.0 (1.0–11.0) | 0.0–18.0 |
| HAQ-s score, median (IQR) | 912 | 0.4 (0.0–0.8) | 0.0–3.0 |
| Peripheral manifestations and EMMs | |||
| Uveitis, n (%) | 895 | 308 (34.4) | -- |
| Peripheral arthritis, n (%) | 894 | 276 (30.9) | -- |
| Psoriasis, n (%) | 895 | 150 (16.8) | -- |
| IBD1, n (%) | 897 | 96 (10.7) | -- |
| Dactylitis, n (%) | 897 | 60 (6.7) | -- |
| Depression, n (%) | 905 | 94 (10.4) | -- |
| Current therapies | |||
| Anti-TNF, n (%) | 912 | 531 (58.2) | -- |
| IL-17 pathway inhibitor, n (%) | 912 | 14 (1.5) | -- |
| Methotrexate, n (%) | 903 | 48 (5.3) | -- |
| Sulfasalazine, n (%) | 903 | 33 (3.7) | -- |
| NSAID, n (%) | 903 | 461 (51.1) | -- |
| Multiple therapies, n (%) | 912 | 275 (30.2) | -- |
| No current therapy, n (%) | 912 | 127 (13.9) | -- |
1 Defined as ulcerative colitis or Crohn’s disease